Your browser doesn't support javascript.
loading
Determination of four homogeneous subgroups of patients with antiphospholipid syndrome: a cluster analysis based on 509 cases.
Nguyen, Yann; Yelnik, Cécile M; Morel, Nathalie; Paule, Romain; Stammler, Romain; Plaçais, Léo; Sacré, Karim; Godeau, Bertrand; Maillard, Hélène; Launay, David; Morell-Dubois, Sandrine; Dupré, Anastasia; Lefèvre, Guillaume; Devloo, Cécile; Dufrost, Virginie; Benhamou, Ygal; Levesque, Hervé; Leroux, Gaëlle; Piette, Jean-Charles; Mouthon, Luc; Hachulla, Éric; Lambert, Marc; Le Guern, Véronique; Costedoat-Chalumeau, Nathalie.
Affiliation
  • Nguyen Y; National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France.
  • Yelnik CM; Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université de Paris, Paris, France.
  • Morel N; Department of Internal Medicine and Clinical Immunology, Referral Centre for Centre for Rare Systemic Autoimmune Diseases North and North-West of France (CeRAINO), CHU Lille, Univ. Lille, Inserm, U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Paule R; National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France.
  • Stammler R; Department of Internal Medicine, Hôpital Foch, Suresnes, France.
  • Plaçais L; National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France.
  • Sacré K; National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France.
  • Godeau B; Department of Internal Medicine, Hôpital Bichat, AP-HP Nord, Université de Paris, Paris, France.
  • Maillard H; Department of Internal Medicine, Hôpital Mondor, AP-HP, Université de Paris-Est Créteil, Créteil, France.
  • Launay D; Department of Internal Medicine and Clinical Immunology, Referral Centre for Centre for Rare Systemic Autoimmune Diseases North and North-West of France (CeRAINO), CHU Lille, Univ. Lille, Inserm, U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Morell-Dubois S; Department of Internal Medicine and Clinical Immunology, Referral Centre for Centre for Rare Systemic Autoimmune Diseases North and North-West of France (CeRAINO), CHU Lille, Univ. Lille, Inserm, U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Dupré A; Department of Internal Medicine and Clinical Immunology, Referral Centre for Centre for Rare Systemic Autoimmune Diseases North and North-West of France (CeRAINO), CHU Lille, Univ. Lille, Inserm, U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Lefèvre G; National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France.
  • Devloo C; Department of Internal Medicine and Clinical Immunology, Referral Centre for Centre for Rare Systemic Autoimmune Diseases North and North-West of France (CeRAINO), CHU Lille, Univ. Lille, Inserm, U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Dufrost V; Department of Internal Medicine and Clinical Immunology, Referral Centre for Centre for Rare Systemic Autoimmune Diseases North and North-West of France (CeRAINO), CHU Lille, Univ. Lille, Inserm, U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Benhamou Y; Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, University of Lorraine, Inserm U1116, Nancy, France.
  • Levesque H; Department of Internal Medicine, CHU de Rouen, UniRouen, Inserm, U1096, Rouen, France.
  • Leroux G; Department of Internal Medicine, CHU de Rouen, UniRouen, Inserm, U1096, Rouen, France.
  • Piette JC; Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France.
  • Mouthon L; Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France.
  • Hachulla É; National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France.
  • Lambert M; Department of Internal Medicine and Clinical Immunology, Referral Centre for Centre for Rare Systemic Autoimmune Diseases North and North-West of France (CeRAINO), CHU Lille, Univ. Lille, Inserm, U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Le Guern V; Department of Internal Medicine and Clinical Immunology, Referral Centre for Centre for Rare Systemic Autoimmune Diseases North and North-West of France (CeRAINO), CHU Lille, Univ. Lille, Inserm, U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Costedoat-Chalumeau N; National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France.
Rheumatology (Oxford) ; 62(8): 2813-2819, 2023 08 01.
Article in En | MEDLINE | ID: mdl-36190346
ABSTRACT

OBJECTIVE:

APS is a heterogeneous disease with different phenotypes. Using an unsupervised hierarchical cluster analysis, we aimed to determine distinct homogeneous phenotypes among APS patients.

METHODS:

We performed an observational, retrospective study of APS patients enrolled in the French multicentre 'APS and SLE' registry who met the Sydney classification criteria. The clustering process involved an unsupervised multiple correspondence analysis followed by a hierarchical ascendant clustering analysis; it used 27 variables selected to cover a broad range of APS clinical and laboratory manifestations.

RESULTS:

These analyses included 509 patients, mainly women (77.8%). Mean (s.d.) age at APS diagnosis was 36.2 (14.6) years, and mean follow-up since diagnosis 10.3 (8.5) years. This hierarchical classification cluster analysis yielded four homogeneous groups of patients cluster 1, mostly with venous thromboembolism without any associated autoimmune disease; cluster 2, older, lowest proportion of women, history of arterial events, and/or with migraines, arterial hypertension, diabetes mellitus, or dyslipidaemia; cluster 3, younger, highest proportion of women, associated SLE or other autoimmune diseases, and a history of venous thromboembolism or pregnancy morbidity; and cluster 4, mainly with a history of catastrophic antiphospholipid syndrome, aPL-associated nephropathy, and pregnancy morbidity, with frequent triple positivity and more deaths (16.7%).

CONCLUSIONS:

Our study applied an unsupervised clustering method to distinguish four homogeneous APS patient subgroups that were predominantly venous; arterial; associated with SLE or another autoimmune disease; and arterial microthrombotic. Heterogeneous pathophysiological mechanisms may explain these findings.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thrombosis / Antiphospholipid Syndrome / Venous Thromboembolism / Kidney Diseases Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Male / Pregnancy Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2023 Document type: Article Affiliation country: Francia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thrombosis / Antiphospholipid Syndrome / Venous Thromboembolism / Kidney Diseases Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Male / Pregnancy Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2023 Document type: Article Affiliation country: Francia